Login / Signup

Long-term safety of approved biologics for ulcerative colitis.

Ferdinando D'AmicoTommaso Lorenzo ParigiStefanos BonovasLaurent Peyrin-BirouletSilvio Danese
Published in: Expert opinion on drug safety (2020)
Biologics long-term safety is consistent with what expected from shorter term studies and no main new concerns emerged from longer follow-up. Real world experience is consistent with clinical trials data. Although comparisons are difficult, safety profiles are not equal among different biologics.
Keyphrases
  • clinical trial
  • ulcerative colitis
  • randomized controlled trial
  • electronic health record
  • machine learning
  • big data
  • open label
  • study protocol
  • phase ii